SEC Company Response from Quince Therapeutics, Inc. (QNCX) (CIK 0001662774) (IRLA) — Apr 9, 2020
Quince Therapeutics, Inc. (QNCX) (CIK 0001662774)
Date: April 9, 2020 · CIK: 0001662774 · Accession: 0001193125-20-102554
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-237594
Letter
269 East Grand Ave.
South San Francisco, CA 94080
April 9, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Chris Edwards, Office of Life Sciences
Re:
Cortexyme, Inc.
Registration Statement on Form S-1
Filed April 7, 2020
File No. 333-237594
REQUEST FOR ACCELERATION OF EFFECTIVENESS
Acceleration Request
Requested Date:
April 13, 2020
Requested Time:
4:00 p.m. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Cortexyme, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to declare the Company’s Registration Statement on Form S-1 (File No. 333-237594) effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Company hereby authorizes Niki Fang, who is an attorney with the Company’s outside legal counsel, Orrick, Herrington & Sutcliffe LLP, to orally modify or withdraw this request for acceleration.
The Company requests that it be notified of such effectiveness by a telephone call to Ms. Fang at (415) 773-5540.
[Signature page follows]
Sincerely,
CORTEXYME, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP 269 East Grand Ave. South San Francisco, CA 94080 April 9, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Chris Edwards, Office of Life Sciences Re: Cortexyme, Inc. Registration Statement on Form S-1 Filed April 7, 2020 File No. 333-237594 REQUEST FOR ACCELERATION OF EFFECTIVENESS Acceleration Request Requested Date: April 13, 2020 Requested Time: 4:00 p.m. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Cortexyme, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to declare the Company’s Registration Statement on Form S-1 (File No. 333-237594) effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable. The Company hereby authorizes Niki Fang, who is an attorney with the Company’s outside legal counsel, Orrick, Herrington & Sutcliffe LLP, to orally modify or withdraw this request for acceleration. The Company requests that it be notified of such effectiveness by a telephone call to Ms. Fang at (415) 773-5540. [Signature page follows] Sincerely, CORTEXYME, INC. By: /s/ Christopher Lowe Name: Christopher Lowe Title: Chief Financial Officer cc: Casey C. Lynch, Cortexyme Inc. Ted Monohon, Cortexyme Inc. Scott M. Iyama, Esq., Orrick, Herrington & Sutcliffe LLP Niki Fang, Esq., Orrick, Herrington & Sutcliffe LLP